Prittle Prattle Pr

Category: Pharmacy

  • Pharma’s Next Big Shift: BCG & IPSO Chart India’s CRDMO Path to a $25 Billion Global Opportunity

    A new BCG-IPSO report highlights how India’s CRDMO firms are scaling talent, infrastructure, and innovation to capture a larger share of the $145 billion global pharma outsourcing market.

    India’s Contract Research, Development, and Manufacturing Organization (CRDMO) sector is undergoing a transformation, with projections placing it at $25 billion by 2035. A new report, “Unleashing the Tiger: Indian CRDMO Sector 2025”, published by Boston Consulting Group (BCG) and Innovative Pharmaceutical Services Organization (IPSO), outlines India’s growing influence in global pharmaceutical innovation.
    The report highlights how eleven leading CRDMO firms have joined forces under IPSO to move beyond traditional outsourcing. The goal is to position India as a leader in biologics, RNA therapeutics, and advanced drug development, with strong support from government-backed initiatives and global supply chain shifts.

    India’s CRDMO market is expanding at a 15% CAGR, surpassing global industry growth. As pharmaceutical companies diversify manufacturing beyond China, India’s expertise in small molecules, biologics, and Antibody Drug Conjugates (ADCs) presents a major advantage. The report states that global supply chain realignments are unlocking a $10 billion opportunity for Indian CRDMOs.
    Peter Bains, CEO Designate of Syngene International Ltd., emphasized that India is no longer just a low-cost outsourcing hub but is advancing towards high-value pharmaceutical innovation. He stated that IPSO’s efforts would accelerate India’s leadership in cutting-edge drug research and biomanufacturing.

    IPSO’s Role in India’s CRDMO Expansion
    IPSO is bringing together leading Indian CRDMOs, including Syngene International, Aragen Life Sciences, Piramal Pharma Solutions, Sai Life Sciences, Neuland Laboratories, Aurigene, and Jubilant Biosys. This coalition aims to enhance India’s drug discovery capabilities, strengthen regulatory frameworks, and promote international partnerships.
    Manni Kantipudi, CEO of Aragen Life Sciences, noted that IPSO represents a strategic shift for the Indian CRDMO sector. He highlighted that India must move beyond small-molecule manufacturing and focus on biologics, ADCs, and gene therapies to capture a larger share of the $145 billion global CRDMO market.
    Vikash Agarwalla, Managing Director at BCG, emphasized that while India’s cost advantage, talent pool, and policy support are strong, the industry must address critical funding, regulatory, and sustainability challenges to fully capitalize on the $25 billion potential.

    Key Challenges on the Road to $25 Billion
    Despite strong growth, India’s CRDMO sector must overcome several challenges to achieve its full potential. The BCG-IPSO report outlines five key areas that require immediate attention:
    India needs to scale its talent pool by 6-7x by 2035, particularly in biologics, ADCs, and gene therapy. The regulatory approval process must be streamlined to enable faster clinical trials and drug approvals. IPSO is advocating for a more competitive regulatory framework to help Indian firms compete with United States, European Union, and Japan in securing global partnerships.
    India currently imports a significant portion of its Active Pharmaceutical Ingredients (APIs), making supply chain resilience a key focus. Strengthening the domestic Tier 1 supplier base is crucial to reducing dependence on imports. Capital investment in CRDMOs needs to increase by 4-5x to build world-class R&D infrastructure. IPSO is working with policymakers to encourage financial incentives for research, manufacturing, and digital transformation.
    With global pharma firms adopting Environmental, Social, and Governance (ESG) compliance standards, Indian CRDMOs need to align with sustainable manufacturing practices to remain competitive in international markets.

    Global Pharma’s Shift: India’s Growing Influence in CRDMO
    The global pharmaceutical industry is evolving, and India is emerging as a preferred destination for contract research and drug development.
    Pharmaceutical giants are actively diversifying their supply chains, with a shift away from China to India and Southeast Asia. Regulatory policies such as the US Inflation Reduction Act (IRA) are encouraging offshoring to cost-effective hubs like India. Additionally, the Indian government’s ₹25,000 crore R&D investment is fueling the country’s rise as a center for biologics, cell and gene therapy, and next-generation drug manufacturing.
    Smruthi Suryaprakash, Partner at BCG, explained that IPSO is helping Indian CRDMOs move beyond outsourcing to full-scale drug discovery. She noted that India is now competing with the world’s top pharmaceutical research hubs and has the potential to become a leader in high-value drug manufacturing.

    India’s CRDMO Future: A $25 Billion Global Opportunity
    With IPSO driving collaboration, India’s CRDMO sector is poised to play a central role in global pharmaceutical research and manufacturing. The next decade will determine whether India can fully capitalize on its scientific expertise, infrastructure, and policy advantages to secure a larger share of the global pharma market.

    At Prittle Prattle News, featuring you virtuously, we celebrate the commitment and innovation. Led by Editor-in-Chief Smruti Bhalerao, our platform is dedicated to sharing impactful stories that inspire change and create awareness. Follow us on LinkedIn, Instagram, and YouTube for more stories that matter.

  • Swiss CDMO Senn Chemicals Acquired to Fuel Granules India’s Peptide Drug Development

    The acquisition of Senn Chemicals enhances Granules India’s capabilities in peptide therapeutics, targeting anti-diabetic, anti-obesity, and next-generation APIs

    Granules India (BSE: 532482, NSE: GRANULES) has signed an agreement to acquire Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organization (CDMO) specializing in peptide synthesis. This strategic acquisition will accelerate Granules’ entry into the high-growth peptide API market, particularly in anti-diabetic and anti-obesity therapeutics, including GLP-1 receptor agonists.
    The transaction is expected to close in the first half of 2025, subject to regulatory approvals and customary closing conditions.

    Granules India Expands into Peptide-Based Drug Development
    By acquiring Senn Chemicals, Granules India gains proprietary expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), which are critical for developing high-purity peptide-based drugs. The deal also strengthens Granules’ CDMO business, allowing it to collaborate with leading pharmaceutical innovators across therapeutics, cosmetics, and amino acid derivatives (AADs).
    Senn Chemicals operates a state-of-the-art facility in Switzerland, certified under ISO 9001:2015 and regularly inspected by Swissmedic. Under the Mutual Recognition Agreement (MRA) with the U.S. Food and Drug Administration (FDA), Swissmedic’s cGMP inspections are recognized by the FDA, providing a direct regulatory pathway for Granules’ peptide-based drug expansion into the U.S. market.

    Strategic Impact: Strengthening Peptide API & CDMO Leadership
    With this acquisition, Granules India enters the growing peptide-based pharmaceutical segment, focusing on next-generation metabolic treatments. The company is actively developing two GLP-1-based APIs in collaboration with Senn Chemicals, with additional peptide-based Active Pharmaceutical Ingredients (APIs) in the pipeline.
    The acquisition also enables Granules to:
    Leverage Senn’s established customer relationships with global pharma companies
    Expand into Europe’s high-value peptide CDMO market
    Enhance peptide-based API production with advanced synthesis technology
    Meet the rising demand for peptide-based drugs, particularly for type 2 diabetes and obesity management

    Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, highlighted the strategic importance of the acquisition:
    “Acquiring Senn Chemicals AG marks a milestone in Granules’ expansion into next-generation peptide therapeutics. With Senn’s expertise in peptide synthesis and our large-scale, cost-efficient manufacturing, we aim to become a global leader in peptide-based solutions. This acquisition aligns with our vision to transform Granules into an innovation-driven pharmaceutical company and strengthen our CDMO business worldwide.”
    Dr. Rico Wiedenbruch, Chairman, Senn Chemicals AG, also emphasized the partnership’s potential:
    “Joining forces with Granules India presents a unique opportunity to scale our peptide innovations. With Granules’ expertise in high-volume manufacturing and regulatory excellence, we can expand our reach in the growing peptide-based pharmaceutical and CDMO segments while continuing to serve our global clients with best-in-class solutions.”

    CDMO Expansion: Leveraging Senn’s European Presence
    The acquisition also propels Granules India into the CDMO (Contract Development and Manufacturing Organization) market, allowing the company to:

    • Enhance R&D and manufacturing for complex peptide-based APIs
    • Expand its footprint in Europe, leveraging Senn’s presence in Switzerland
    • Access highly skilled peptide scientists and regulatory-compliant facilities
    • Strengthen relationships with leading pharmaceutical innovators and biotech firms

    By integrating Senn’s CDMO business with its existing API and finished dosage production capabilities, Granules India aims to scale its peptide operations globally while improving cost efficiencies in high-value drug development.

    Advisors on the Acquisition
    Granules India was advised by Stifel Nicolaus India as the exclusive financial advisor.
    Legal advisory was provided by Loyens & Loeff, while Deloitte conducted financial and tax due diligence.
    Kroll provided valuation advisory services for the transaction.
    Founded in 1963, Senn Chemicals AG is a Swiss-based CDMO specializing in custom peptide synthesis and amino acid derivatives. The company provides contract research, development, and manufacturing services for pharmaceutical, cosmetic, and theragnostic applications.
    Senn’s core capabilities include:
    • Liquid-Phase Peptide Synthesis (LPPS) & Solid-Phase Peptide Synthesis (SPPS)
    • Analytical method development & process optimization
    • cGMP and non-GMP manufacturing for peptide APIs
    • Scalability from early-stage clinical trials to commercial production
    With its Swissmedic-approved facility and expertise in next-generation peptide synthesis, Senn Chemicals is a trusted partner for global pharmaceutical and biotech companies.
    Granules India is a vertically integrated pharmaceutical company headquartered in Hyderabad, India. Founded in 1991, the company has:
    • 10 global manufacturing facilities (8 in India, 2 in the U.S.)
    • Regulatory approvals from US FDA, EDQM, EU GMP, TGA, and more
    • A product portfolio spanning APIs, Pharmaceutical Formulation Intermediates (PFIs), and Finished Dosages (FDs)
    • Distribution in 80+ countries with a customer base of over 300 clients
    Granules India is committed to expanding into complex and specialized therapeutics, with a focus on innovation, affordability, and global accessibility.
    At Prittle Prattle News, featuring you virtuously, we celebrate the commitment and innovation. Led by Editor-in-Chief Smruti Bhalerao, our platform is dedicated to sharing impactful stories that inspire change and create awareness. Follow us on LinkedIn, Instagram, and YouTube for more stories that matter.